1.
First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis
2.
3.
4.
5.
A cost-utility analysis of transcatheter aortic valve implantation in Belgium: focusing on a well-defined and identifiable population
6.
7.